Adicet Bio Revenue and Competitors
Estimated Revenue & Valuation
- Adicet Bio's estimated annual revenue is currently $42.7M per year.
- Adicet Bio's estimated revenue per employee is $251,250
- Adicet Bio's total funding is $145.6M.
Employee Data
- Adicet Bio has 170 Employees.
- Adicet Bio grew their employee count by 24% last year.
Adicet Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Quality Assurance | Reveal Email/Phone |
2 | VP, Vector Development and QC | Reveal Email/Phone |
3 | VP, Cell Therapy Development and Manufacturing | Reveal Email/Phone |
4 | VP, Head Human Resources | Reveal Email/Phone |
5 | VP and Head Clinical Operations | Reveal Email/Phone |
6 | VP Biometrics | Reveal Email/Phone |
7 | VP Quality Assurance | Reveal Email/Phone |
8 | VP Translational Medicine | Reveal Email/Phone |
9 | VP Program Development | Reveal Email/Phone |
10 | VP, Nonclinical Development | Reveal Email/Phone |
Adicet Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Adicet Bio?
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology. Adicet Bio raised $51M in series A financing led by OrbiMed Partners, OrbiMed Israel, Novartis Venture Fund and Pontifax.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$145.6M
Total Funding
170
Number of Employees
$42.7M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Adicet Bio News
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer.
(RTTNews) - Adicet Bio, Inc. (ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta...
The U.S. Food and Drug Administration (FDA) granted fast track designation to Adicet Bio's (NASDAQ:ACET) lead program ADI-001 to treat...
MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Michael G. Kauffman, M.D. ...
Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors Menlo Park, CA and Boston, MA - November 18, 2021 - Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other d ...
Other Companies in Menlo Park
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $27.3M | 171 | N/A | N/A |
#2 | $47.6M | 173 | 8% | N/A |
#3 | $31.2M | 177 | 26% | N/A |
#4 | $27.4M | 177 | -12% | N/A |
#5 | $28.6M | 179 | 4% | N/A |